List of Excipients in Branded Drug CLOFARABINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Winthrop US a business of sanofi-aventis US LLC	CLOFARABINE	clofarabine	0955-1746	SODIUM CHLORIDE
Winthrop US a business of sanofi-aventis US LLC	CLOFARABINE	clofarabine	0955-1746	WATER

Generic Drugs Containing CLOFARABINE

Company	Ingredient	NDC	Excipient
Accord Healthcare Inc	clofarabine	16729-431	SODIUM CHLORIDE
Accord Healthcare Inc	clofarabine	16729-431	WATER
DrReddy's Laboratories Inc	clofarabine	43598-309	SODIUM CHLORIDE
Zydus Lifesciences Limited	clofarabine	49315-003	SODIUM CHLORIDE
Zydus Lifesciences Limited	clofarabine	49315-003	WATER

What are the Most Frequently-Used Excipients in CLOFARABINE?

# Of NDCs	Excipient
12	SODIUM CHLORIDE
10	WATER

Excipient Strategy and Commercial Opportunities for Clofarabine

Last updated: February 28, 2026

What is the Role of Excipients in Clofarabine Formulations?

Excipients are inactive substances in drug formulations that enhance stability, bioavailability, and patient compliance. For clofarabine, a nucleoside analog used in hematologic malignancies, excipient selection affects manufacturing, shelf-life, and delivery.

What Are the Key Excipients Utilized in Clofarabine Formulations?

Currently, clofarabine is formulated primarily as an injectable solution. The typical excipient profile includes:

• Buffer agents: Phosphate buffer maintains pH stability.
• Preservatives: Polysorbate 80 or similar stabilizers prevent microbial growth.
• Solvents: Water for injection forms the base solution.
• Cryoprotectants: For lyophilized forms, excipients like sucrose or mannitol are common.

The exact formulation is proprietary but aligns with standard cytotoxic agents' injectable formulations.

How Does Excipient Optimization Impact Clofarabine's Commercial Potential?

Optimized excipient strategies can improve drug stability, extend shelf life, and simplify manufacturing:

• Enhanced stability: Allows easier logistics and reduces waste.
• Reduced manufacturing costs: Streamlined excipient profiles can lower production expenses.
• Patient compliance: Formulations with fewer excipients or improved tolerability can boost usage.

Particularly, developing a lyophilized form with stabilizing excipients could expand shelf life from several months to multiple years, enabling broader distribution.

What Are the Emerging Opportunities in Excipient Development for Clofarabine?

Innovations include:

• Novel stabilizers: Using excipients like trehalose to improve stability.
• Targeted delivery systems: Incorporating excipients that facilitate nanoparticle or liposomal formulations.
• Reduced preservative use: Developing preservative-free formulations for sensitive patient populations.

These advancements could differentiate cloFarabine offerings and open new markets.

What Are the Regulatory and Commercial Challenges?

Regulatory pathways require validation of excipient safety, especially for new excipients or delivery systems. Compatibility with existing manufacturing processes must be demonstrated. Market entry hinges on demonstrating advantages over existing formulations and cost-effectiveness.

What Market Opportunities Exist with Excipient Innovation?

Target markets include:

• Oncology treatment centers: Demand for stable, reliable formulations.
• Global markets: Opportunities in regions with cold chain limitations through shelf-life extension.
• Special populations: Pediatric or immunocompromised patients benefit from preservative-free preparations.

Introducing improved formulations with optimized excipients can command higher pricing and market share, particularly in indications like refractory leukemias or lymphomas where cloFarabine is indicated.

Summary Table: Comparative Insights

Aspect	Current Clofarabine Formulation	Potential Improvements	Commercial Impact
Packaging	vials, usually refrigerated	lyophilized, enhanced stability	reduces logistical costs
Excipient profile	standard buffers, preservatives	novel stabilizers, targeting delivery	increases shelf life, reduces waste
Market focus	hospital infusions	outpatient, or home infusion	broadens customer base

Key Opportunities & Strategies:

• Develop lyophilized formulations with stabilizers like trehalose.
• Invest in nanoparticle or liposomal formulations utilizing excipients promoting targeted delivery.
• Focus on preservative-free solutions for sensitive patient groups.
• Collaborate with regulatory bodies early to streamline approval.

Key Takeaways

• Excipient selection is critical for maintaining cloFarabine's stability and bioavailability.
• Innovations in excipient chemistry can extend shelf life and reduce manufacturing costs.
• Emerging delivery systems leveraging excipients can improve targeting and tolerability.
• Regulatory and manufacturing considerations must align with development plans.
• Market expansion depends on demonstrating benefits over existing formulations.

FAQs

1. What are the main excipients used in cloFarabine formulations?
   Buffer agents like phosphate buffers, stabilizers such as polysorbate 80, water for injection, and cryoprotectants like sucrose are used.

2. Can new excipients improve cloFarabine's stability?
   Yes, excipients like trehalose or nanocarrier-based excipients can enhance stability and shelf life.

3. Are there advantages to transitioning to a lyophilized formulation?
   Yes, lyophilized forms typically have longer shelf life, easier storage, and more flexible distribution.

4. What are the regulatory considerations for excipient modifications?
   Regulators require safety data, compatibility testing, and validation studies for new excipients or delivery systems.

5. How can excipient innovation impact market penetration?
   Improved formulations can reduce costs, expand access, and enable use in special populations, broadening the market.

---

References

[1] U.S. Food and Drug Administration. (2020). Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics. FDA.
[2] European Medicines Agency. (2017). Reflection Paper on the Use of Surfactants as Excipients in Medicinal Products. EMA.
[3] Blume, H., & Rautio, J. (2018). Nanocarrier-based drug delivery systems: Opportunities and challenges. International Journal of Pharmaceutics, 540(1-2), 1-3.